Table 5. COVID-19 related symptoms and duration in study participants in Lesotho and Zambia.
| Lesotho N = 426* |
Zambia N = 1136** |
||||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Asymptomatic | 164 | 38.5 | 937 | 82.5 | |
| Symptomatic *** | 262 | 61.5 | 199 | 17.5 | |
| Symptoms | Cough | 183 | 69.9 | 147 | 73.9 |
| Fever | 36 | 13.7 | 38 | 19.1 | |
| Shortness of breath | 6 | 2.3 | 21 | 10.6 | |
| Loss of taste or smell | 17 | 6.5 | 30 | 15.1 | |
| Weight loss | 25 | 9.5 | 22 | 11.1 | |
| Chest Pain | 21 | 8.0 | 49 | 24.6 | |
| Night sweats | 15 | 5.7 | 28 | 14.1 | |
| Symptom duration (among those symptomatic) | any symptom for ≤ 3 days | 167 | 63.7 | 109 | 54.8 |
| any symptom for ≤ 7 days | 246 | 93.9 | 183 | 92.0 | |
* In Lesotho, for two participants, data was incomplete
** In Zambia, one participant, despite being enrolled was not symptom screened
*** In Zambia symptomatic participant were those who had either fever, cough, shortness of breath or loss of taste and/or smell, whereas in Lesotho symptomatic participants were participant with either cough, fever as reported by the patient, shortness of breath, loss of taste or smell, pronounced tiredness, sore throat, muscle or body pain, diarrhea, weight loss, night sweat, chest pain, headache, rash on skin.